Amwell's Q1 2021 results showed a revenue increase of 7% year-over-year to $57.6 million. Total active providers increased by 240% to approximately 81,000, and total visits increased by 120% to 1.6 million. The company's net loss was $39.8 million, and adjusted EBITDA was $(26.4) million, impacted by increased R&D investment in the Converge technology platform.
Total active providers reached approximately 81,000, a 240% increase year-over-year.
Total visits amounted to 1.6 million, representing a 120% increase compared to the previous year.
First quarter revenue increased 7% year-over-year to $57.6 million.
Net loss was $39.8 million and adjusted EBITDA was $(26.4) million due to increased R&D investment.
Amwell reiterates their previous outlook for 2021.
Analyze how earnings announcements historically affect stock price performance